# SKB103 for Injection in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07459998/  
OnCo record `nct07459998` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SKB103 for injection monotherapy in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

SKB103 for Injection in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07459998 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 277 participants planned, started 2026-04-23 and due to reach its primary completion in 2029-12-31. Interventions recorded: SKB103 for injection monotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07459998
- Phase: 1/2
- Setting: A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SKB103 for Injection in Participants With Advanced Solid Tumors
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 277

## Sources

- ClinicalTrials.gov NCT07459998: https://clinicaltrials.gov/study/NCT07459998

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07459998.json